Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;47(3):379-393.
doi: 10.1016/j.rdc.2021.04.005. Epub 2021 Jun 16.

T Cells in Systemic Lupus Erythematosus

Jacqueline L Paredes  1 , Ruth Fernandez-Ruiz  2 , Timothy B Niewold  3
Affiliations
Review

T Cells in Systemic Lupus Erythematosus

Jacqueline L Paredes et al. Rheum Dis Clin North Am. 2021 Aug.

Abstract

T-cell dysregulation has been implicated in the loss of tolerance and overactivation of B cells in systemic lupus erythematosus (SLE). Recent studies have identified T-cell subsets and genetic, epigenetic, and environmental factors that contribute to pathogenic T-cell differentiation, as well as disease pathogenesis and clinical phenotypes in SLE. Many therapeutics targeting T-cell pathways are under development, and although many have not progressed in clinical trials, the recent approval of the calcineurin inhibitor voclosporin is encouraging. Further study of T-cell subsets and biomarkers of T-cell action may pave the way for specific targeting of pathogenic T-cell populations in SLE.

Keywords: Cytokines; Epigenetics; Lupus; Metabolism; Systemic lupus erythematosus; T cells; T-cell subsets.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement and funding T.B. Niewold: grants from the Colton Center for Autoimmunity, NIH (AR060861, AR057781, AR065964, AI071651), the Lupus Research Foundation, and the Lupus Research Alliance; T.B. Niewold has received research grants from EMD Serono and Janssen, Inc, and has consulted for Thermo Fisher, Toran, Ventus, Roivant Sciences, and Inova, all unrelated to the current article. R. Fernandez-Ruiz and J.L. Paredes have nothing to disclose.

Figures

Figure 1.
Figure 1.
CD4+ T cell subsets relevant in SLE.
See this image and copyright information in PMC

References

    1. Suárez-Fueyo A, Bradley SJ, Tsokos GC. T cells in Systemic Lupus Erythematosus. Curr Opin Immunol. 2016;43:32–38. - PMC - PubMed
    1. Katsuyama T, Tsokos GC, Moulton VR. Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Front Immunol. 2018;9:1088. - PMC - PubMed
    1. Deng Q, Luo Y, Chang C, Wu H, Ding Y, Xiao R. The Emerging Epigenetic Role of CD8+T Cells in Autoimmune Diseases: A Systematic Review. Front Immunol. 2019;10:856. - PMC - PubMed
    1. Sharabi A, Tsokos GC. T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nat Rev Rheumatol. 2020;16(2):100–112. - PubMed
    1. Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5–17. - PMC - PubMed

Publication types